Clinical-stage biotechnology firm Entropy Neurodynamics (ASX:ENP) has announced a major strategic victory with the granting of an Australian patent for its proprietary psychedelic administration method.
The patent fortifies the intellectual property landscape for the company’s lead asset, TRP-8803, an intravenous psilocin formulation designed to treat psychological and nociplastic pain disorders.
The newly secured patent provides long-dated protection through 2042, covering a unique two-phase dosing regimen.
The method involves an initial loading dose followed by a controlled maintenance infusion, creating a predictable pharmacokinetic profile that is difficult to achieve via traditional oral administration.
By utilising an IV-based approach, clinicians can induce a therapeutic state within 5 to 30 minutes and, crucially, terminate the treatment immediately if necessary by stopping the infusion—a safety feature that oral psychedelics cannot match.
Beyond dosing, the patent claims extend to the use of EEG-based monitoring for real-time biomarker development and cover a broad spectrum of conditions, including PTSD, anxiety, and eating disorders.
By securing protection over the specific methods of administration rather than just the chemical compound, Entropy Neurodynamics has established a formidable "competitive moat."
At the time of reporting, Entropy Neurodynamics' share price was $0.033.